Nicholas Hill, MD
Pulmonary Disease · Boston, MANPI 1558308874
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Sanofi at 48.0% of the total. Reporting peaked in 2019 at $138,358 and has fallen 91.1% since, to $12,368 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $1062.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$141K
- Boehringer Ingelheim$37K
- Genentech USA, Inc.$26K
- Fisher & Paykel Healthcare Limited$25K
- Merck$12K
- Philips North America LLC$11K
- plus $40K from 21 others
Across 136 payments — averaging $3556.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$300K
- Insmed, Inc.$58K
- Sumitomo Pharma America, Inc.$55K
- Fisher & Paykel Healthcare Limited$34K
- Novartis$29K
- Actelion Pharmaceuticals, Ltd$3K
- plus $3K from 1 others
What the payments were for
- Consulting fees$105,46736%
- Speaking & faculty fees$133,90246%
- Travel & lodging$44,70115%
- Food & beverage$8,9993%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 106 | $140,724 |
| Boehringer Ingelheim | 19 | $37,052 |
| Genentech USA, Inc. | 19 | $26,162 |
| Fisher & Paykel Healthcare Limited | 5 | $25,302 |
| Merck | 19 | $12,452 |
| Philips North America LLC | 3 | $11,338 |
| Fisher & Paykel Healthcare Inc | 14 | $8,866 |
| Breas Medical, Inc. | 4 | $6,875 |
| United Therapeutics Corporation | 26 | $6,352 |
| GSK | 7 | $5,069 |
| Inogen, Inc. | 3 | $4,050 |
| CSL Behring | 1 | $3,254 |
| Upjohn US 1 LLC | 1 | $3,000 |
| Actelion Pharmaceuticals US, Inc. | 29 | $1,517 |
| Vapotherm Inc | 1 | $350 |
| Abbott | 1 | $162 |
| AstraZeneca | 5 | $111 |
| Livanova USA, Inc. | 1 | $110 |
| Sandoz | 2 | $95 |
| Johnson & Johnson(2 entities) | 3 | $76 |
| Bayer | 1 | $52 |
| Paratek Pharmaceuticals, Inc. | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Aero US Inc | 1 | $31 |
| Liquidia Technologies, Inc. | 1 | $25 |
| Insmed, Inc. | 1 | $18 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIZYME$99,454
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment$21,535
- FISHER & PAYKEL HEALTHCARE$14,626
- NEXVIAZYME$12,321
- Vivo 45 LS$6,875
- (2858) General Consulting$5,640
- TRELEGY ELLIPTA$4,889
- ORENITRAM$4,274
- US Enabling function$3,348
- VIAGRA$3,000
- InogenOne$2,700
- (8599) Chief Medical Officer$2,350
- DISEASE STATE$1,977
- INOGEN$1,350
- TYVASO$452
- VAPOTHERM$350
- REMODULIN$333
- UPTRAVI$315
- OFEV$275
- OPSUMIT$207
How this compares
$293,130 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 22 | $700,782 |
| OfevNintedanib Esylate | 15 | $194,420 |
| Ambrisentan | 44 | $188,658 |
| OpsumitMacitentan | 12 | $153,841 |
| Sildenafil Citrate | 22 | $9,261 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,047 |
| Prednisone | 24 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,517 | $854,62434 claims |
| Boehringer IngelheimOfev | $37,052 | $194,42015 claims |
| GSKIncruse Ellipta | $5,069 | $4,04712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.